Phase 2 Endometrial Neoplasms Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Ovarian NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms+3 more
Yonsei University198 enrolled27 locationsNCT06023862
Recruiting
Phase 2
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Neoplasm MetastasisEndometrial NeoplasmsNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute30 enrolled1 locationNCT06532539
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
MalignancyMelanomaCancer+7 more
Cancer Research UK30 enrolled27 locationsNCT05770102
Recruiting
Phase 1Phase 2
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Carcinoma, Non-Small Cell LungOvarian NeoplasmsColorectal Neoplasms+3 more
Eli Lilly and Company540 enrolled49 locationsNCT04956640
Recruiting
Phase 2Phase 3
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
Xiaojun Chen80 enrolled2 locationsNCT05316935
Recruiting
Phase 2Phase 3
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
ObesityEndometrial NeoplasmsAtypical Endometrial Hyperplasia+1 more
Xiaojun Chen29 enrolled2 locationsNCT06379113
Recruiting
Phase 2
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Endometrial CancerEndometrial Neoplasms
Yonsei University30 enrolled1 locationNCT05795244
Recruiting
Phase 2
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Endometrial CancerEndometrial CarcinomaRecurrent Endometrial Carcinoma+2 more
Yonsei University92 enrolled6 locationsNCT06502743